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Background/Aims: Hepatocellular carcinoma (HCC) patients 
with spinal metastasis (SM) show heterogeneous lengths of 
survival. In this study, we develop and propose a graded prog-
nostic assessment for HCC patients with SM (HCC-SM GPA). 
Methods: We previously reported the outcomes of 192 HCC 
patients with SM who received radiotherapy from April 1992 
to February 2012. Prognostic factors that significantly af-
fected survival in that study were used to establish the HCC-
SM GPA. Validation was performed using an independent co-
hort of 63 patients recruited from September 2011 to March 
2016. Results: We developed the HCC-SM GPA using the 
following factors: Eastern Cooperative Oncology Group perfor-
mance status (0–2, 0 point; 3–4, 1 point), controlled primary 
HCC (yes, 0 point; no, 2 points), and extrahepatic metasta-
ses other than bone (no, 0 point; yes, 1 point). Patients were 
stratified into low (GPA=0), intermediate (GPA=1 to 2), and 
high risk (GPA=3 to 4). When applied to the validation cohort, 
the HCC-SM GPA determined median survival durations of 
13.6, 4.8, and 2.6 months and 1-year overall survival rates of 
58.3%, 17.8%, and 7.3% for the low-, intermediate-, and high-
risk patient groups, respectively (p<0.001). Conclusions: Our 
newly proposed HCC-SM GPA successfully predicted survival 
outcomes. (Gut Liver 2017;11:535-542)
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INTRODUCTION
Although hepatocellular carcinoma (HCC) is a lethal disease, 
the prognosis of patients with HCC has improved continuously 
in recent decades, subsequent to the development of diagnostic 
tools and treatment modalities.1-3 Consequently, bone metasta-
ses of HCC have become a more frequent occurrence.1,2
Spinal metastasis (SM) occurs in 50% to 75% of cases of 
bone metastases of HCC and can lead to neurologic deficits and 
a reduced quality of life.4-8 Surgery can provide restoration of 
mechanical instability and emergent decompression,9,10 while 
chemotherapy can be used to treat systemically with targeted 
agent such as sorafenib.11-14 Radiotherapy (RT) can effectively 
provide palliation of painful SM in approximately 60% to 97% 
of patients, with up to 32% of patients experiencing a complete 
response in terms of pain relief.4,15,16 Although spinal involve-
ment is thought to indicate a poor prognosis,5,16 patients with 
SM exhibit widely variable survival durations, and certain pa-
tients have favorable lifespans of up to 2 years.3,4,15 In our previ-
ous report, the follow-up times of patients ranged from 0.5 to 
125 months, and 32 of 192 patients (16.7%) survived for longer 
than 1 year.4 These findings suggest the necessity of accurate 
survival predictions that could be used to identify different 
prognostic groups and determine the intensity of treatment ac-
cordingly.
A graded prognostic assessment (GPA) can be defined as a 
prognosis-predictive scoring model derived from clinical fac-
tors found to affect survival. Following the development of a 
GPA for brain metastases by the Radiation Therapy Oncology 
Group,17,18 similar models have been developed for breast can-
cer19 and HCC,20 and several prognosis-predictive scoring mod-
els have been used for SM.21-23 However, an HCC-specific SM 
GPA has not previously been developed. 
Accordingly, the present study aimed to develop a HCC-SM 
GPA that could be used to classify patients according to risk 
groups and apply treatment according to prognosis.
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MATERIALS AND METHODS
1. Patient population 
In our previous study, we reported the clinical outcomes of 
192 HCC patients with SM who received RT at Yonsei Cancer 
Center from April 1992 to February 2012. These patients were 
defined as the training group, and significant prognostic factors 
identified through a multivariate analysis were used to develop 
the HCC-SM GPA. To validate our HCC-SM GPA, we recruited 
an independent cohort of 63 patients who presented with HCC 
with SM at two independent hospitals with a shared university 
affiliation, Yonsei Cancer Center and Gangnam-Severance Hos-
pital (45 and 18 patients, respectively) from September 2011 to 
March 2016. 
2. Evaluation of primary tumor progression and assessment 
of SM
A controlled primary tumor was defined as a lack of evidence 
of HCC in the liver on follow-up imaging studies conducted 
after treatment for HCC.4 SM was characterized by multiplicity, 
a mass-type nature, spinal cord compression, and pathologic 
fracture due to metastasis.4 A mass-type metastasis was defined 
as a soft tissue mass associated with bone lesion outside of the 
spine. Spinal cord compression was defined as radiologic tumor 
involvement of the spinal canal with neurologic symptoms 
(American Spinal Injury Association [ASIA] impairment scale of 
A, B, or C).24 Pathologic fracture was defined as a fracture due 
to a metastasis of HCC.
3. Statistical analysis
Overall survival was measured from the time of RT initia-
tion. The Breslow test, which has been identified as superior for 
detecting early differences,25 was used to compare the survival 
outcomes of different risk groups. All statistical analyses were 
performed using SPSS version 20.0 (IBM Corp., Armonk, NY, 
USA). All p-values <0.05 were considered statistically signifi-
cant.
RESULTS
1. Patient characteristics
In the training group, which had a median follow-up period 
of 4.2 months (range, 0.3 to 124.8 months) and median age of 
55.5 years (range, 20 to 82 years), 181 patients (94.3%) were 
followed until death. The majority of patients in this group were 
men (157, 81.7%) and had a Child-Pugh class status of A (70.8%). 
In addition, most patients (54.2%) had an Eastern Cooperative 
Oncology Group (ECOG) performance status of ≤2.
The validation group had a median follow-up period of 4.3 
months (range, 0.3 to 28.8 months) and median age of 60 years 
(range, 38 to 82 years). In this group, 56 of 63 patients (88.9%) 
were followed until death. Most of patients were men (93.7%) 
and had a Child-Pugh class status of A (76.2%) and ECOG per-
formance score of 0–2 (88.9%).
2. GPA for HCC patients with SM 
In our previous study, the ECOG performance status, con-
trolled status of primary HCC, extrahepatic metastases other 
than bone, and biologic equivalent dose (BED) of RT were 
identified as statistically significant prognostic factors affecting 
survival (Table 1). Because the BED is a treatment-related factor 
that cannot be used to predict outcomes prior to treatment, it 
was not included in our HCC-SM GPA. To construct the HCC-
SM GPA, we obtained a prognostic score for each factor using 
the partial score method,26,27 wherein each partial score was 
calculated by dividing the each magnitude of the regression 
coefficient by the smallest statistically significant regression 
coefficient and rounding each derived value to the nearest in-
teger or the nearest integer plus 0.5. Finally, these partial scores 
were summed to calculate a GPA score for each patient. The 
parameters for which partial scores were derived were the ECOG 
performance status (0–2, 0 point; 3–4, 1 point), controlled status 
of primary HCC (controlled, 0 point; uncontrolled, 2 points), 
and extrahepatic metastases other than bone (no, 0 point; yes, 
1 point). Scores of 0 and 4 were considered the best and worst 
predictive prognostic scores, respectively. Partial scores of 
the included factors and a definition of the HCC-SM GPA are 
shown in Table 2. After calculating the HCC-SM GPA by sum-
ming the partial scores of each factor, we divided the scores to 
form three risk groups: score of 0, low-risk group; scores of 1 to 
2, intermediate-risk group; and scores of 3 to 4, high-risk group.
In the training group, overall survival times among all risk 
groups were significantly different (p<0.001), between low- and 
intermediate-groups (p=0.001), and between intermediate- and 
high-risk groups (p=0.002). The median survival periods were 5.9 
(95% confidence interval [CI], 4.9 to 6.8; n=101), 3.4 (95% CI, 
2.2 to 4.6; n=81), and 1.0 (95% CI, 0.7–1.3; n=10) months for 
the low-, intermediate-, and high-risk groups, respectively, with 
corresponding 6-month survival rates of 49.0%, 24.8%, and 
10.0%, respectively (Fig. 1). 
3. Validation
We applied the HCC-SM GPA to our validation cohort, and 
observed significant differences in survival times among the 
risk groups (Fig. 2). The survival outcomes differed significantly 
among all subgroups (p<0.001), as well as between the low- 
and intermediate-risk groups (p=0.014) and the intermediate- 
and high-risk groups (p<0.009). The median survival durations 
were 13.6 (95% CI, 2.0 to 25.2; n=12), 4.8 (95% CI, 1.9 to 7.6; 
n=19), and 2.6 (95% CI, 1.5 to 3.7; n=32) months for the low-, 
intermediate-, and high-risk groups, respectively, with corre-
sponding 6-month survival rates of 91.7%, 47.4%, and 21.8%, 
respectively. The summarized results are shown in Table 3.
As compared to training group, the validation group has 
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Table 1. Prognostic Factor Analyses for Overall Survival of the Training Group
Univariate analysis Multivariate analysis
No. of patients MS, mo p-value* Coefficient HR 95% CI p-value†
Age, yr 0.492 - - - -
    ≤55 86 4.8 
    >55 106 3.9
Gender 0.430 - - - -
    Male 157 4.5
    Female 35 5.3
ECOG performance status <0.001 0.639 1.895 1.302–2.757 0.001
    0–2 104 5.7
    3–4 88 2.7
AFP, ng/mL 0.143 - - - -
    ≤200 98 4.7
    >200 94 2.8
Child-Pugh classification 0.025 0.259 1.165 0.693–1.755 0.164
    A, B 172 4.5
    C 20 2.0
Primary HCC <0.001 1.279 3.595 2.453–5.268 <0.001
    Controlled 127 6.2
    Uncontrolled 65 1.9
Interval from diagnosis of primary tumor to  
  spinal metastases, mo
0.966 - - - -
    ≤9 100 4.2
    >9 92 4.0
Baseline BPI score (pain severity) 0.857 - - - -
    ≤6 114 4.8
    >6 78 4.2
Extrahepatic metastases other than bone 0.012 –0.560 0.571 0.391–0.835 0.004
    Yes 50 2.8
    No 142 5.0
Site of spinal metastasis 0.169 - - - -
    Cervical 26 2.5
    Thoracic 46 4.8
    Lumbar 48 5.7
    Sacrum 8 4.5
    Combined (2 sites or more) 64 3.7
Multiplicity of spinal metastases 0.112 - - - -
    Yes 105 5.0
    No 87 3.9
Mass-type metastases 0.577 - - - -
    Yes 46 4.7
    No 146 4.5
Spinal cord compression (ASIA scale A–C) 0.839 - - - -
    Yes (A–C) 25 4.0
    No (D, E) 167 4.5
Pathologic fracture 0.003 –0.342 0.710 0.476–1.059 0.093
    Yes 47 2.7
    No 145 5.0
BED, Gy10 <0.001 –0.624 0.536 0.383–0.751 <0.001
    ≤38 38 2.4
    39–53 132 9.7
    >53 22 15.2
Treatment modalities 0.926 - - - -
    RT alone 140 3.9
    RT+CTx 38 4.0
    RT+S±CTx 14 5.3
RT technique 0.110 - - - -
    Conventional (2D) 107 3.9
    3D-CRT of IMRT 85 4.5
Pain response 0.001 0.308 1.361 0.938–1.973 0.104
    CR 41 7.2
    Non-CR 151 3.0
Adapted from Choi C, Seong J. Gut Liver 2015;9:94-102.4
MS, median survival; HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; AFP, α-fetoprotein; HCC, hepatocel-
lular carcinoma; BPI, brief pain inventory; ASIA, American Spinal Injury Association; BED, biologically effective dose; RT, radiotherapy; CTx, 
chemotherapy; S, surgery; 2D, 2-dimensional; 3D-CRT, 3-dimensional conformal radiation therapy; IMRT, intensity-modulated radiation therapy; 
CR, complete pain response. 
*Determined using the log-rank test; †Determined using the Cox proportional hazard model.
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more patients with uncontrolled primary HCC (65.1% vs 15.6%, 
p<0.001) and extrahepatic metastases other than bone (61.9% 
vs 26.0%, p<0.001). There was no statistically significant dif-
ference in patient distribution according to ECOG performance 
status (p=0.377). The result of survival analysis of the validation 
group is presented in Table 4.
DISCUSSION
In the present study, we analyzed a total of 255 HCC patients 
with SM, including 192 patients who were used to develop 
the HCC-SM GPA and 63 patients recruited for validation. We 
found that the risk groups stratified according to our HCC-SM 
GPA exhibited significant differences in survival outcomes.
Several previous studies have reported various prognos-
tic factors that affect the survival of HCC patients with SM. 
Chang et al.15 conducted one of the largest studies, evaluating 
102 HCC patients with SM. The median survival interval from 
SM to death was 3 months, and a good performance status 
and response to RT were found to significantly affect survival. 
Goodwin et al.3 performed a meta-analysis of 26 studies that 
described operative techniques used to treat SM. The authors re-
ported that patients who underwent surgery plus adjuvant ther-
apy, including chemotherapy or RT, displayed a trend toward 
Table 2. Definition of HCC-SM GPA 
Magnitude of coefficient Partial score
GPA
0 1 2
ECOG performance 0.639 1 0–2 3–4
Primary controlled 1.279 2 Controlled Uncontrolled
Extrahepatic metastases other than bone 0.571 1 No Yes
HCC, hepatocellular carcinoma; SM, spinal metastasis; GPA, graded prognostic assessment; ECOG, Eastern Cooperative Oncology Group perfor-
mance status. 
Table 3. Survival Results in the Validation Group According to the GPA Score
GPA score No. MS 95% CI 1 yr OS, % 6 mo OS, % p-value
Low risk 0 12 13.6   2.0–25.2 58.3 91.7 ] 0.014 ] <0.001 Intermediate risk 1–2 19   4.8 1.9–7.6 17.8 47.4 ] 0.009 High risk 3–4 32   2.6 1.5–3.7   7.3 21.8
GPA, graded prognostic assessment; MS, median survival; CI, confidence interval; OS, overall survival.
Fig. 2. Survival outcomes in the validation group according to the 
graded prognostic assessment for hepatocellular carcinoma patients 
with spinal metastasis (HCC-SM GPA). The risk groups were defined 
as follows: low-risk group, GPA score 0; intermediate-risk group, 
GPA scores 1 to 2; and high-risk group, GPA scores 3 to 4. Overall 
survival differed among all subgroups (p<0.001), between the low-
risk and intermediate-risk groups (p=0.014), and between the inter-
mediate-risk and high-risk groups (p=0.009).
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Fig. 1. Survival outcomes in the training group according to the 
graded prognostic assessment for hepatocellular carcinoma patients 
with spinal metastasis (HCC-SM GPA). The risk groups were defined 
as follows: low risk group, GPA score 0; intermediate risk group, GPA 
scores 1 to 2; and high risk group, GPA scores 3 to 4. Overall survival 
differed among all subgroups (p<0.001), between the low-risk and 
intermediate-risk groups (p=0.001), and between the intermediate-
risk and high-risk groups (p=0.002). 
RT, radiotherapy.
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Table 4. Prognostic Factor Analysis for Overall Survival of the Validation Group
Univariate analysis Multivariate analysis
No. of patients MS, mo p-value* Coefficient HR 95% CI p-value†
Age, yr 0.058 - - - -
    ≤55 20 3.4
    >55 43 5.8
Gender 0.567 - - - -
    Male 59 4.8
    Female 4 2.0
ECOG performance status <0.001 2.584 13.244 4.606–38.079 <0.001
    0–2 56 5.8
    3–4 7 1.4
AFP, ng/mL <0.001 1.284 3.613 1.873–6.967 <0.001
    ≤200 32 9.8
    >200 31 3.0
Child-Pugh classification <0.001 2.868 17.610 5.262–58.933 <0.001
    A, B 58 4.8
    C 5 0.4
Primary HCC 0.004 1.054 2.869 1.425–5.778 0.003
    Controlled 22 9.0
    Uncontrolled 41 3.4
Interval from diagnosis of primary tumor to  
  spinal metastases, mo
0.692 - - - -
    ≤12 28 3.7
    >12 35 5.8
Baseline BPI score (pain severity) 0.887 - - - -
    ≤6 40 4.8
    >6 20 4.5
Extrahepatic metastases other than bone <0.001 1.213 3.362 1.676–6.743 0.001
    Yes 39 2.7
    No 24 9.8
Site of spinal metastasis 0.051 - - - -
    Cervical 2 10.5
    Thoracic 13 6.4
    Lumbar 6 7.3
    Sacrum 4 13.8
    Combined (2 sites or more) 38 3.7
Multiplicity of spinal metastases 0.013 0.635 1.887 0.976–3.648 0.059
    Yes 41 3.7
    No 22 8.9
Mass-type metastases 0.200 - - - -
    Yes 29 3.7
    No 34 5.8
Spinal cord compression (ASIA scale A–C) 0.025 –0.072 0.930 0.424–2.040 0.857
    Yes (A–C) 17 3.4
    No (D, E) 46 5.8
Pathologic fracture 0.301 - - - -
    Yes 22 3.4
    No 41 5.2
BED, Gy10 0.010 –0.038 0.963 0.398–2.329 0.932
    ≤38 29 3.0
    39–53 23 7.6
    >53 11 8.9
Treatment modalities 0.228 - - - -
    RT alone 24 5.8
    RT+CTx 27 3.7
    RT+S±CTx 12 8.9
RT technique 0.913 - - - -
    3D-CRT or conventional 2D 39 4.5
    IMRT or tomotherapy 24 4.8
Pain response 0.209 - - - -
    CR 13 8.8
    Non-CR 47 4.3
MS, median survival; HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; AFP, α-fetoprotein; HCC, hepatocel-
lular carcinoma; BPI, brief pain inventory; ASIA, American Spinal Injury Association; BED, biologically effective dose; RT, radiotherapy; CTx, 
chemotherapy; S, surgery; 3D-CRT, 3-dimensional conformal radiation therapy; 2D, 2-dimensional; IMRT, intensity-modulated radiation therapy; 
CR, complete pain response. 
*Determined using the log-rank test; †Determined using the Cox proportional hazard model.
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longer survival when compared to patients treated with either 
modality alone or subjected to observation. The other clinical 
prognostic factors were not reported due to low or insufficient 
statistical strength, because most of the recruited studies were 
case series. Other studies reported age, Child-Pugh class, Kar-
nofsky performance status scale, and Tomita score (Table 5) as 
significant factors affecting survival.14,16,28 However, reports of 
these prognostic factors were heterogeneous, and the number 
of studies and number of patients included in each study were 
relatively small. Therefore, the available information about these 
previously identified prognostic factors was not sufficient to 
make treatment decisions.
Previously, other authors attempted to stratify the risks of 
patients with SM and suggested treatment strategies. For ex-
ample, the Tomita and Tokuhashi scoring systems, which were 
developed by orthopedic surgeons, are popular models used to 
predict the prognosis of patients with SM from various can-
cers.21,22 The Tomita system includes prognostic parameters of 
the primary tumor site, visceral metastases, and multiplicity of 
bone metastasis, whereas the Tokuhashi system incorporates the 
performance status, number of non-spinal bone metastases, ma-
jor organ metastasis, primary tumor site, and degree of palsy.29 
However, these systems are not easily applied to HCC patients 
with SM, as survival of HCC patients is largely affected by the 
primary cancer control status. Furthermore, those systems rec-
ommend treatment strategies that mainly focus on spinal sur-
gery, rather than other modalities such as RT or primary cancer 
treatment.
As noted above, the GPA was originally developed as a prog-
nostic index and quantitative evaluation tool to help clinicians 
make treatment decisions regarding patients with brain me-
tastases. The GPA has been widely implemented because of its 
comprehensive nature, ease of use, and good ability to predict 
prognosis.17,18 Since the original GPA was developed for brain 
metastases regardless of any primary cancer, is also not easily 
applied to HCC. Thus disease specific HCC-GPA was developed 
and has been clinically useful.20 A similar HCC-specific GPA is 
needed for patients with SM. Our HCC-SM GPA incorporated 
three important and well-known prognostic factors: ECOG per-
formance status, primary HCC control status, and extrahepatic 
metastases other than bone. Furthermore, the HCC-SM GPA was 
based on a relatively large number of patients and was designed 
for simplicity and ease of use.
Use of the HCC-SM GPA for patient stratification will allow 
physicians to apply tailored treatment options according to an 
individual patient’s life expectancy. The low-risk group, charac-
terized by a favorable performance status and limited extent of 
non-spinal disease, had a median survival of 13.6 months and 
1-year survival rate of 58.3%. This group might accordingly be 
offered an active therapeutic approach that includes local treat-
ments such as surgery or stereotactic body radiotherapy,14,30-32 
which could ameliorate pain or neurologic symptoms and con-
sequently enhance quality of life, and might even yield a near-
cure of oligometastases.33-36 The intermediate-risk group, which 
had a median survival of 4.8 months and a 6-month survival 
rate of 47.4%, encompasses various clinical conditions, and 
patients in this group should be treated on an individual basis 
with consideration of their performance status and extent of 
metastases. The high-risk group, characterized by uncontrolled 
primary HCC with a poor performance status or a nonspinal 
metastatic burden, had a median survival duration of only 2.6 
months and a 6-month survival rate of 21.8%. For this group, 
supportive and hospice care would be the best option, thus al-
lowing patients to avoid unnecessary physical or economic bur-
dens from medical treatment.
Beyond treatment strategy decisions, our HCC-SM GPA could 
also be applied to clinical trial design; for example, research-
ers could categorize patients according to predicted survival 
and therefore balance the assortment of patients into individual 
groups. Furthermore, this tool would be useful for comparing 
the results of different studies.
Our study had several limitations. First, the number of pa-
tients in the validation cohort was relatively small, and approxi-
mately half of the patients were classified as being at high risk, 
Table 5. Reported Series of Clinical Outcomes of Hepatocellular Carcinoma Patients with Spinal Metastasis 
Author Study type No. Treatment (%)
OS after SM, 
mo 
OS after treatment 
for SM
Prognostic factor
Chang et al.15 Retrospective 102 RT (82.3), OP (8.8) 3 - RT response, ECOG performance
Chang et al.16 Retrospective 27 (SRS group) SRS (100), OP (10.3) 14 7 Age, Child-Pugh class, KPS 
32 (cRT croup) cRT (100) 3
Lee et al.14 Retrospective 33 OP (100), RT (36.4) 8.7 6 Tomita score
Sohn et al.28 Retrospective 28 (SRS group) SRS (100), OP (10.3) - 8 -
28 (cRT group) cRT (100), OP (10.3) 10
Goodwin et al.3 Meta-analysis 26 Articles, 
  152 patients
OP (84.2), RT (61.8) 10.6 - Multimodal treatment
OS, overall survival; SM, spine metastasis; RT, radiotherapy; OP, operation; ECOG, Eastern Cooperative Oncology Group performance status; SRS, 
stereotactic radiosurgery; KPS, Karnofsky Performance Status scale; cRT, conventional RT.
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whereas only 12 were classified as being at low risk. Therefore, 
further verification may be needed. Second, our study included 
only patients who received RT of the spine. The exclusion of 
patients whose conditions were deemed insufficient for RT or 
who did not receive RT because of personal or physicians’ pref-
erences might have introduced bias.
In conclusion, the HCC-SM GPA might facilitate the selec-
tion of patients who are candidates for active local treatment, 
and could identify high-risk patients who would benefit from 
best supportive care. To the best of our knowledge, the HCC-SM 
GPA, which includes prognostic factors identified in a relatively 
large, disease-specific study, is the first HCC-specific prognostic 
model for SM. Further validation and utilization in various pa-
tient groups are warranted to establish its efficacy.
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